首页>投融资
4D Molecular Therapeutics
增发
4D Molecular Therapeutics, Inc.于2015年3月11日根据特拉华州法律成立。该公司是一家临床阶段基因治疗公司，开创了利用其靶向和进化的AAV载体开发候选产品的先河。
基本信息
-
公司全称4D Molecular Therapeutics LLC
-
类型基因治疗药物研发商
-
产业领域药品研发/制造、生物药
-
公司人数101~500人
-
地址5858 Horton Street #455 Emeryville California 94608
-
联系电话1-510-5052680
-
邮箱info@4dmoleculartherapeutics.com
-
成立时间2013-01-01
投融资
-
2023-05-09增发1.38亿美元未透露
-
2023-05-09增发13800万美元未透露
-
2021-10-28增发未透露未透露
-
2020-12-11上市1.80亿美元未透露
-
2020-12-10IPO1.047亿美元未透露
-
2020-12-10上市1.047亿美元未透露
-
2020-06-16C轮7500万美元Pfizer VenturesPappas CapitalChiesi VenturesPerceptive AdvisorsAmzak Health InvestorsRidgeback CapitalQUADLongevity Vision FundOctagon Investments Master FundBVF PartnersArrowMark PartnersBCFCasdin CapitalViking Global InvestorsCF FoundationMirae Asset Financial Group
-
2020-06-16C轮7500万美元辉瑞Casdin CapitalAmzak Health InvestorsChiesi VenturesLongevity Vision FundQUADRidgeback CapitalPappas CapitalPerceptive AdvisorsOctagon Investments Master FundMirae Asset Financial GroupBCFArrowMark PartnersCF FoundationBVF PartnersViking Global Investors
-
2018-09-05B轮9000万美元Pfizer VenturesPappas CapitalChiesi VenturesCureDuchenne VenturesPerceptive AdvisorsRidgeback CapitalArrowMark PartnersBCFJanus Henderson InvestorsViking Global InvestorsMirae Asset Financial Group
-
2018-09-05B轮9000万美元辉瑞Chiesi VenturesPappas CapitalCureDuchenne VenturesRidgeback CapitalPerceptive AdvisorsMirae Asset Financial GroupArrowMark PartnersBCFJanus Henderson InvestorsViking Global Investors
-
2017-09-19未公开300万美元CF Foundation
-
2017-09-19未透露300万美元CF Foundation
-
2015-08-13未公开700万美元未透露
-
2015-08-13未透露700万美元未透露
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息